136 filings
Page 6 of 7
8-K
aw0cir4 16s745jm7
22 Oct 07
Departure of Directors or Principal Officers
12:00am
8-K
p9ka iae6no
3 Oct 07
Entry into a Material Definitive Agreement
12:00am
8-K
pge ogq3la
7 Aug 07
Idenix Pharmaceuticals Reports Second Quarter
12:00am
8-K
jklssnv1gdkr7bil
16 Jul 07
Valopicitabine Development Program Placed on Clinical Hold In the United States
12:00am
8-K
kaq71ccubpoy5f
19 Jun 07
Departure of Directors or Principal Officers
12:00am
8-K
4es9usu
26 Apr 07
Idenix Pharmaceuticals Reports First Quarter Financial Results
12:00am
8-K
swo1m4ccpxf
3 Apr 07
Departure of Directors or Principal Officers
12:00am
8-K
bprcxb7i51mnsjz6w
21 Mar 07
Idenix Pharmaceuticals, Inc. Announces Resignation of Chief Financial Officer
12:00am
8-K
m775g6ddc58r61ed5m
12 Mar 07
Departure of Directors or Principal Officers
12:00am
8-K
2jl8480qf f3vbvx
2 Mar 07
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
12:00am
8-K
47q1mu7y zg4h
19 Jan 07
Other Events
12:00am
8-K
g31u24s60
12 Jan 07
Idenix Pharmaceuticals, Inc. Announces Appointment of Douglas Mayers, M.D. As Executive Vice President and Chief Medical Officer
12:00am
8-K
pfqrpu6
8 Dec 06
Norman C. Payson, M.D., Elected to Board of Directors of Idenix Pharmaceuticals
12:00am
8-K
oy5clf5yzbqa9mb2v
27 Oct 06
Results of Operations and Financial Condition
12:00am
8-K
21u 1kv8oeowa9uu
8 Sep 06
Entry into a Material Definitive Agreement
12:00am
8-K
3rgc kwi2sb
3 Aug 06
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
12:00am
8-K
ypvxb71a yt
28 Jun 06
Entry into a Material Definitive Agreement
12:00am
8-K
h3jugplk88fn2
2 May 06
Idenix Pharmaceuticals Reports First Quarter Financial Results
12:00am
8-K
mblntq6d569fha365g
29 Mar 06
Idenix Announces Licensing of Valopicitabine (NM283) by Novartis
12:00am
8-K
90yb9zu6 jgf
23 Mar 06
Idenix Provides Update on Clinical Development of Valopicitabine (NM283) for the Treatment of Hepatitis C
12:00am